1. Search Result
Search Result
Results for "

non-enzymatic protein

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139427

    β-Methylglutaconic acid

    GABA Receptor Cardiovascular Disease Neurological Disease Metabolic Disease
    3-Methylglutaconic acid is the major metabolites accumulating in 3-Methylglutaconic aciduria (MGTA). 3-Methylglutaconic acid can induce lipid oxidative damage and protein oxidative. 3-Methylglutaconic acid decreases the non-enzymatic antioxidant defenses in cerebral cortex supernatants to elicit oxidative stress in the cerebral cortex. 3-Methylglutaconic acid can be used for brain damage disease research .
    3-Methylglutaconic acid
  • HY-141508

    Xanthine Oxidase NO Synthase Neurological Disease Metabolic Disease Inflammation/Immunology
    Flazin is a non-enzymatic protein glycation inhibitor, also inhibits peroxynitrite (ONOO -), with an IC50 value of 85.31 μM for bovine serum albumin (BSA) glycation and an EC50 value of 71.99 μM for ONOO -. Flazin can be used for researching diabetes and neuronal disorders. Flazin also can used as a lipid droplet (LD) regulator against lipid disorders, and a xanthine oxidase (XOD) inhibitor .
    Flazin
  • HY-113033A

    Others Neurological Disease
    Pentosidine TFA is a fluorescent advanced glycation end product (AGE) and crosslink. Pentosidine can serve as a biomarker for non-enzymatic modification of long-lived proteins by the Maillard reaction, providing insight into the overall role of the Maillard reaction in aging and disease .
    Pentosidine TFA
  • HY-N12840

    Others Metabolic Disease
    Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .
    Logmalicid B
  • HY-W286743

    CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine

    Biochemical Assay Reagents Cardiovascular Disease Metabolic Disease Cancer
    Nε-(Carboxymethyl)-L-lysine (CML) is a unique post-translational modification (PTM) of proteins that is generated by the non-enzymatic glycation of lysine residues. Nε-(Carboxymethyl)-L-lysine is a relatively recently discovered modification, and has been found to be a major component of the advanced glycation endproducts (AGEs) found in multiple human diseases, such as diabetes, Alzheimer’s disease, and cancer .
    Nε-(Carboxymethyl)-L-lysine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: